TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

M8 Pharmaceuticals, an Acino Company, Enters Exclusive Partnership with SERB Pharmaceuticals to Launch Voraxaze® (Glucarpidase) in Latin America

Thursday, March 21, 2024

M8 Pharmaceuticals, an Acino company, and SERB Pharmaceuticals have formed a partnership to introduce a crucial cancer treatment to Latin America. In this collaboration, M8 will manage the registration, marketing, and commercialization of SERB's supportive oncology drug Voraxaze® (glucarpidase) across the region.

Voraxaze® is a carboxypeptidase known for its ability to significantly reduce toxic plasma methotrexate levels in both adults and children facing delayed methotrexate elimination or at risk of methotrexate toxicity. With an efficacy of ≥97% reduction in just 15 minutes, Voraxaze® plays a crucial role in mitigating severe toxicities and fatalities. Approved in the US since 2012 and also available in Europe and Japan, Voraxaze® is endorsed in the US National Comprehensive Cancer Network guidelines.

Antoine Bernasconi, Executive VP and Chief Commercial Officer for EMEA/International at SERB, expressed pride in partnering with M8, emphasizing their shared commitment to addressing unmet patient needs. This collaboration marks a significant stride in SERB's global expansion, aiming to extend vital treatments to more patients worldwide.

Joel Barlan, Head of Latin America at Acino, echoed this sentiment, expressing excitement about the collaboration's potential to provide solutions for high medical needs in Latin America, leveraging SERB's expertise in treating complex and life-threatening conditions.

This partnership resonates with M8's mission to enhance access to innovative medicines in Latin America, particularly in the fields of onco-hematology and rare diseases. By joining forces, the two companies aim to reach a larger number of patients in urgent need, offering life-saving treatments in underserved regions.

High Dose Methotrexate (HDMTX) chemotherapy, employed in treating various cancers such as leukemia, lymphoma, and osteosarcoma, can sometimes lead to high levels of methotrexate in the body, causing acute renal toxicity and other adverse reactions. Voraxaze®, when administered where approved, swiftly reduces methotrexate levels, averting further systemic damage by breaking it down into inactive metabolites, primarily eliminated via the liver.

SERB Pharmaceuticals, with over 30 years of expertise, specializes in emergency care and rare diseases, boasting a diverse portfolio of medicines. Their commitment to supporting clinicians, healthcare systems, and governments aligns perfectly with the mission of extending hope to patients and their families. SERB's extensive antidote portfolio includes medical countermeasures for various risks, including chemical, biological, radiological, and nuclear threats.

As a fully integrated company, SERB possesses the capabilities to acquire, develop, and manufacture medicines to the highest standards, ensuring their availability worldwide through a secure supply chain. In the US, SERB operates under the name BTG Pharmaceuticals.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit